Record HEPLISAV-B® quarterly net product revenue of $92 million , representing 31% year-over-year growth

Refines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million , from $305 to $325 million

Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025

Completed dosing in Part 1 of Phase 1/2 trial of pandemic influenza adjuvant program

Conference call today at 4:30 p.m. ET / 1:30 p.m. PT

EMERYVILLE, Calif. , Aug. 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended June 30, 2025 .

"In the second quarter

See Full Page